Hospital acquired infections can create several complications for patients. These infections, caused due to multidrug resistant organisms, drastically reduce the convalescence of a patient and is often accompanied with comorbidities.

Conventional antibiotics fail to curb such infections, since these organisms are multidrug resistant. Pneumonia is one of the most common infections caused due to prolonged stays in hospital premises. Instances of hospital acquired infections are most common among patients with weak immunity, such as elderly and infant patients. Post-surgical infections and infections caused due to enteral feeding constitute the common cases of hospital acquired diseases. High prevalence of hospital acquired pneumonia is likely to boost the pipeline for hospital acquired pneumonia therapeutics.

To study the prospects of the pipeline for global hospital acquired pneumonia drugs Market, Transparency Market Research has released a report titled “Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”. The report states that the six drugs currently in phase III of testing are likely to generate total revenue of US$3.8 billion by the end of 2020.

Browse the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report at http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html

The report has identified that the stage III of pipeline analysis currently has five investigational drugs and one vaccine. Ten other candidates have successfully entered the early stages of pipeline analysis. Drugs that have reached phase III of clinical trials include AstraZeneca PLC’s Ceftazidime/avibactam, Achaogen, Inc’s Plazomicin, GlaxoSmithKline’s Synflorix, Ceftolozane/tazobactam, Bayer Healthcare’s Amikacin inhale, and Tedizolid phosphate by Cubist Pharmaceuticals. If approved, these drugs could be available in the market by 2017. The report has stated that mostly biological drugs have entered the last stage of clinical trials. This shows a paradigm shift from antibiotics drugs to novel biological drugs.

Increasing incidence of drug resistance has emerged as a major concern among hospitals around the world. The Centers of Disease Control and Prevention (CDC) conducted a survey in the U.S., which revealed 63% of Acinetobacter variants are multidrug resistant. Among the hazardous organisms spurring ventilator-associated pneumonia, methicillin-resistant Staphylococcus aureus (MRSA) is the most prominent. According to the CDC, almost 80,400 MRSA infections were registered in 2011, among which deaths of almost 11,000 patients were reported. Additionally, it was also revealed by the World Health Organization (WHO) that nosocomial infections are more common in low- and middle-income economies. Hence, it is only obvious that the situation regarding hospital acquired pneumonia is alarming in these regions.


Browse the full Press Release:http://www.transparencymarketresearch.com/pressrelease/hospital-acquired-pneumonia-drugs.htm


The report published by Transparency Market Research studies how the spread of hospital acquired pneumonia will boost the pipeline of hospital acquired pneumonia drugs. It includes region-based analysis to study the prospects of the pipeline of hospital acquired pneumonia drugs across key regions including North America, Europe, Asia Pacific, and Rest of the World.



To study the market competition, the report has profiled leading market players such as GlaxoSmithKline, Achaogen, Inc., Cubist Pharmaceutical, Bayer Healthcare, Aridis Pharmaceutical, Meiji Seika Pharma Co., Ltd., AstraZeneca PLC, Valneva SE., Merck & Co., and Basilea Pharmaceutica Ltd.

Hospital Acquired Pneumonia, Pipeline Analysis Segments by Phase:
Phase III
Tedizolid phosphate
Ceftolozane/Tazobactam
Ceftazidime/Avibactum
Amikacin Inhale
Plazomicin
Synflorix Vaccine
Early Phase (Phase I & II)
BAL30072
MEDI4893
AR-301 or KBSA301
AR-101 (or KBPA101) and AR-104 (or KBPA104)
AR-201 (or KBRV201)
AR-401 (or KBAB401)
ME1100
GSK 2189242A
V114
IC43

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Segmentation, By Geography:
North America
Europe
Asia Pacific
Rest of the World (RoW)

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881


About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.